Malignancies in systemic lupus erythematosus

Alexandra Ladouceur; Hiromi Tissera; Ann E. Clarke; Rosalind Ramsey-Goldman; Caroline Gordon; James E. Hansen; Sasha Bernatsky

doi:10.1016/B978-0-12-814551-7.00048-9

Malignancies in systemic lupus erythematosus

Alexandra Ladouceur, Hiromi Tissera, Ann E. Clarke, Rosalind Ramsey-Goldman, Caroline Gordon, James E. Hansen, Sasha Bernatsky

Medicine, Rheumatology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers.

Original language	English (US)
Title of host publication	Systemic Lupus Erythematosus
Subtitle of host publication	Basic, Applied and Clinical Aspects
Publisher	Elsevier
Pages	461-467
Number of pages	7
ISBN (Electronic)	9780128145517
ISBN (Print)	9780128145524
DOIs	https://doi.org/10.1016/B978-0-12-814551-7.00048-9
State	Published - Jan 1 2020

Keywords

breast cancer
cancer incidence
cervical cancer
endometrial cancer
HPV
immunosuppressive drugs
lung cancer
lymphoma
malignancy
ovarian cancer
prostate cancer
systemic lupus erythematosus

ASJC Scopus subject areas

Medicine(all)
Immunology and Microbiology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-814551-7.00048-9

Cite this

@inbook{06211b3071f0452d97df8d83cf587de5,

title = "Malignancies in systemic lupus erythematosus",

abstract = "This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers.",

keywords = "breast cancer, cancer incidence, cervical cancer, endometrial cancer, HPV, immunosuppressive drugs, lung cancer, lymphoma, malignancy, ovarian cancer, prostate cancer, systemic lupus erythematosus",

author = "Alexandra Ladouceur and Hiromi Tissera and Clarke, {Ann E.} and Rosalind Ramsey-Goldman and Caroline Gordon and Hansen, {James E.} and Sasha Bernatsky",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-814551-7.00048-9",

language = "English (US)",

isbn = "9780128145524",

pages = "461--467",

booktitle = "Systemic Lupus Erythematosus",

publisher = "Elsevier",

}

TY - CHAP

T1 - Malignancies in systemic lupus erythematosus

AU - Ladouceur, Alexandra

AU - Tissera, Hiromi

AU - Clarke, Ann E.

AU - Ramsey-Goldman, Rosalind

AU - Gordon, Caroline

AU - Hansen, James E.

AU - Bernatsky, Sasha

PY - 2020/1/1

Y1 - 2020/1/1

N2 - This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers.

AB - This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers.

KW - breast cancer

KW - cancer incidence

KW - cervical cancer

KW - endometrial cancer

KW - HPV

KW - immunosuppressive drugs

KW - lung cancer

KW - lymphoma

KW - malignancy

KW - ovarian cancer

KW - prostate cancer

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85133988081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133988081&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-814551-7.00048-9

DO - 10.1016/B978-0-12-814551-7.00048-9

M3 - Chapter

AN - SCOPUS:85133988081

SN - 9780128145524

SP - 461

EP - 467

BT - Systemic Lupus Erythematosus

PB - Elsevier

ER -

Malignancies in systemic lupus erythematosus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this